Results 141 to 150 of about 494,085 (317)

BioRePortAP, an electronic clinical record coupled with a database : an example of its use in a single [PDF]

, 2010
Aims: To evaluate the efficacy and safety of the treatment of psoriatic arthritis (PsA) patients with tumor necrosis factor (TNF) antagonists in the Rheumatology Department of Hospital de Santa Maria using the BioRePortAP.
Campanilho-Marques, R., Canhao, Helena, Costa, M., Fonseca, João Eurico, Martins, F., Pereira da Silva, José A., Polido-Pereira, J., Ramos, F., Rodrigues, A., Saavedra, M. J.   +9 more
core  

Drug survival of IL‐23 and IL‐17 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Psoriasis affects 2–3% of the population, with numerous biologic options complicating treatment selection. This real‐world study found IL‐23p19 inhibitors offer the longest‐lasting effectiveness and safety. Psoriatic arthritis reduced ustekinumab survival, and prior biologic use impacted persistence, especially for IL‐17 inhibitors.
Leila Motedayen Aval, Zenas Z. N. Yiu, Oras A. Alabas, Christopher E. M. Griffiths, Nick J. Reynolds, Philip J. Hampton, Catherine H. Smith, Richard B. Warren, BADBIR Study Group   +8 more
wiley   +1 more source

HL-A-antigens and psoriatic arthritis

, 1974
H Zachariae, A Hjortshøoj, F. Kissmeyer‐Nielsen, A Svejgaard, E. Svejgaard, E. Zachariae   +5 more
openalex   +2 more sources

Cyclosporin A in the long-term treatment of psoriatic arthritis [PDF]

, 1996
F Porzio
openalex   +1 more source

Correspondence to: Clinico‐sero‐pathological characteristics of anti‐Ha antisynthetase syndrome

Brain Pathology, EarlyView.
Marie‐Therese Holzer, Robert Biesen, Sarah Tansley, Carsten Dittmayer, Werner Stenzel, Udo Schneider   +5 more
wiley   +1 more source

Evaluation of the risk of heart failure with tumour necrosis factor inhibitors: A large‐scale meta‐analysis in immune‐mediated inflammatory diseases

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Graphical abstract summarising the results of the present systematic review and meta‐analysis on the effect of tumour necrosis factor inhibitors on the risk of heart failure in immune‐mediated inflammatory diseases. CI, confidence interval; IMID, immune‐mediated inflammatory diseases; RCT, randomised controlled trial; RR, risk ratio; TNF, tumour ...
Noémi Ágnes Galajda, Fanni Adél Meznerics, Péter Mátrai, Alíz Fazekas, Anna Sára Lengyel, Mária Veronika Kolonics, Lajos Vince Kemény, Dezső Csupor, Péter Hegyi, Péter Holló, András Bánvölgyi   +10 more
wiley   +1 more source

Deposition of fibrinogen (FR-antigen) in skin diseases. III. Synovial joint membranes in psoriatic arthritis

, 1977
O Fyrand, OJ. Mellbye
openalex   +2 more sources

Systemic treatment of immune checkpoint inhibitor‐induced psoriasis: Inference‐based guidance

Journal of the European Academy of Dermatology and Venereology, EarlyView.
When managing psoriasis, induced or exacerbated by ICI therapy for cancer, there are concerns regarding immunosuppression from systemic agents for the treatment of psoriasis and the potential impact on ICI efficacy. No direct, high‐level evidence exists to address these concerns.
Kim A. Papp, Luis Puig, Jennifer Beecker, Vinod Chandran, Joël Claveau, Javier Cortés, Jan Dutz, Noah I. Hornick, Rosalyn A. Juergens, Barbara Melosky, Anisha B. Patel, Maxwell B. Sauder, Sandeep Sehdev, Vincent Sibaud, Stephanie L. Snow   +14 more
wiley   +1 more source

INCREASED IMMUNE RESPONSE IN THE ACUTE PHASE OF SYSTEMIC LUPUS ERYTHEMATOSUS AND PSORIATIC ARTHRITIS CAUSED BY SERUM FACTORS

, 1978
W Diezel, W. Guenther, H Meffert, N Soennichsen   +3 more
openalex   +1 more source

Etanercept for the Treatment of Human Immunodeficiency Virus-Associated Psoriatic Arthritis [PDF]

, 2000
David M. Aboulafia, Denise Bundow, Kenneth R. Wilske, Ulrike I. Ocas   +3 more
openalex   +1 more source